Robert Ang, MD, explains why a small-aperture IOL is "not a niche product"

News
Video

At the 2025 ASCRS meeting, Dr Ang said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery

At the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) meeting in Los Angeles, California, Robert Ang, MD, head of cornea and refractive surgery at the Asian Eye Institute in Makati City, Philippines, spoke to the Eye Care Network. He shared the research findings he brought to the ASCRS congress, focused on the IC-8 Apthera small-aperture IOL (Bausch & Lomb).

"For patient selection, first, we are targeting a very important group of patients, who are difficult to treat and also difficult to please," Dr Ang said. "These patients [underwent] these surgeries before because they don't want glasses, and now they don't want glasses again after cataract surgery." According to Dr Ang, a small aperture IOL will benefit all patients, but especially those with complex corneal pathologies and a history of prior surgeries.

"Refractive targeting is very, very crucial. We want them to be between 0.75 to -1," Dr Ang continued, calling this refractive zone the "sweet spot" for small aperture IOL implantation. Accurate and informative keratomety readings are also crucial, he said, though they can be difficult to achieve. "In this tough, tough population, sometimes it's hard to do," he said. "But the good surprise is that even if we miss target, distance vision remains good."

Overall, Dr Ang said he wants clinicians to remember that a small aperture IOL is suitable for a wide range of patient needs. "The small aperture IOL is not a niche product," he emphasised. "Before we [focused on] the challenging, post-refractive patients, we [studied] the population of normal eyes with normal corneas. That's how we found out that this small aperture optic extends depth of focus and gives good intermediate and near vision. So don't hesitate to use them on normal corneas and normal patients...they're applicable to everybody who wants cataract surgery. Just target well and counsel well."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
© 2025 MJH Life Sciences

All rights reserved.